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Cognitive and Psychological Side 
Effects of Antiepileptic Drugs
Katja Eva Brückner
Abstract
Among well-known side effects such as dizziness, nausea, headache and  
diplopia medical treatment of epilepsy may cause side effects on cognition, mood 
and behavior. In special constellations this can profoundly affect compliance with 
the medication as well as quality of life. Some patients are more vulnerable to side 
effects than others. Side effects can have profound impact on the development and 
future life of a patient. Some antiepileptic drugs (e.g. topiramate, zonisamide) show 
a more severe side effect profile than others (e.g. lamotrigine, levetiracetam). Thus, 
in the treatment of epilepsy, it is crucial to consider such possible side effects –  
especially in the beginning of or while changing the medical treatment. Specific 
neuropsychological examinations can monitor side effects on cognitive functions 
like concentration, memory or speech function. If this is not possible in an ambulant 
setting, specific screening instruments and repeated and precise interviews of 
patients and/or relatives can help to discover potential side effects. Because most 
side effects can be reversible, dosage modification or drug replacement is required as 
soon as incompatibilities are discovered.
Keywords: epilepsy, antiepileptic drugs, cognitive side effects, psychological side 
effects
1. Introduction
As one of the most common chronic neurological disorders, epilepsy affects 
many people across all population groups and ages. A prevalence rate of 0.5–1% of 
the population has been assumed [1]. More recent studies on large cohorts report 
even significantly higher rates: there is evidence of a prevalence rate of 1.2% of 
active epilepsy in the population [2]. Active epilepsy means that people diagnosed 
with “epilepsy” have had a seizure within the last 12 months, have seen a doctor 
because of their epilepsy, and/or have been treated with anticonvulsant medication. 
Before starting therapy, it must be clarified whether epilepsy is actually present. 
20–30% of all patients with non-epileptic seizures are incorrectly diagnosed with 
epilepsy [3]. Therefore, differential diagnoses - such as psychogenic non-epileptic 
seizures, cardiovascular fainting, sleep behavior disorders, paroxysmal movement 
disorders or metabolic diseases have to be excluded. A differentiation from non-
disease-relevant, paroxysmally occurring phenomena that do not require therapy 
(e.g. sleep myoclonus) is necessary before initiating therapy.
After a precise diagnosis, clarification of possible differential diagnoses and a 
positive therapy decision, drug treatment is usually the first choice in the treatment 
of epilepsy. Drug therapy is never curative, because the selected medication only 
Epilepsy - Update on Classification, Etiologies, Instrumental Diagnosis and Treatment
2
prevents or reduces seizures in the sense of symptom prophylaxis. The underlying 
cause of epilepsy is not cured with drug treatment. Most patients with epilepsy can 
be easily being treated with medication and, depending on the epilepsy syndrome, 
become seizure-free with monotherapy or combination therapy [4]. Meanwhile, 
many agents with different mechanisms have been approved for the treatment of 
epilepsy. In addition to the desired effect - successful seizure control or a significant 
reduction of seizure frequency - as with all medications, there are also undesirable 
effects with anticonvulsants that are only tolerable to a certain extent and then 
only with a significant improvement in the seizure situation. The tolerable extent 
of these interference effects differs individually and depends on the individual 
situation. In addition to “classic” physical disturbances such as dizziness, nausea, 
headache and double vision, negative effects on cognitive performance and mental 
health are the least tolerated effects. Since drug therapy ideally leads to seizure free-
dom but does not cure epilepsy, in most cases drug treatment is a long-term therapy.
2. Medical treatment
There is a large number of anticonvulsants for drug therapy of epilepsy, 
although those of more recent and of latest generations are not inferior to those of 
the older generation in their anticonvulsant effects. Therefore, a choice must be 
made on the basis of possible interference and interaction profiles and taking into 
account the individual situation of each patient.
Special attention in the treatment decision requires certain patient groups such 
as women of childbearing age because certain anticonvulsants have increased tera-
togenicity. For example, Valproic acid should be avoided due to an increased risk of 
malformation and an unfavorable effect on the later intellectual development of the 
unborn child, especially in higher doses during pregnancy. However, other patient 
groups also need specific consideration: Patients with intellectual disabilities may 
experience an increase in their existing limitations due to paradoxical disturbances 
or drug-related negative effects on cognitive performance. Older patients are 
particularly susceptible to drug interferences due to various co−/multi-morbidities, 
various concomitant medications and the resulting interactions that may not always 
be foreseeable, as well as pharmacodynamics that change due to age.
3. Cognitive side effects of antiepileptic drugs
At the onset of epilepsy and prior to treatment cognitive impairment can be 
already observed in a large number of patients. Frequently detectable deficits  
can be found early in the course of the disease in attention, memory and executive 
functions [5].
Basically, all anticonvulsants can have a negative impact on cognitive perfor-
mance. If any cognitive deficits before treatment existed, these deficits may be 
exacerbated. The most common negative effect of anticonvulsants is a decrease in 
information processing speed, reaction speed and concentration. Most treatment 
related cognitive disorders are reversible and fade after dose reduction or com-
pletely disappear after a change in substance. Only visual field defects with vigaba-
trine are irreversible, which is why this substance has been used only in individual 
cases and under strict ophthalmological control.
Among the anticonvulsants of the older generation valproic acid, carbam-
azepine and phenytoin have the most favorable cognitive side effect profile with 
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comparatively little effects on concentration, memory, information processing 
speed or word fluency. The newer generation of anticonvulsants with a rather 
minor influence on cognitive performance are lamotrigine, levetiracetam, gabapen-
tin, perampanel, lacosamide, oxcarbazepine, eslicarbazepine and pregabalin [6, 7]. 
For lamotrigine and lacosamide - in individual cases also for oxcarbazepine and 
perampanel - improvements in cognitive partial performance (e.g. information pro-
cessing speed, concentration, vigilance) have been described [8–11]. In Contrast, 
topiramate and zonisamide are anticonvulsants with a relatively unfavorable cogni-
tive disturbance profile. However, bromine, phenobarbital and primidone can also 
be associated with cognitive disturbances (e.g. cognitive slowing), whereby these 
substances are rarely used in everyday clinical practice. In combination therapies, 
a frequently condition in refractory epilepsy, undesirable interference effects can 
accumulate.
Topiramate relatively often and sometimes very impressively leads to deteriora-
tion in language skills such as verbal fluency and word finding, to a slowdown in the 
speed of reaction and to decline in working memory. In general, these interference 
effects occur even at relatively low doses and also if the dosage is very slow. In addi-
tion, there does not seem to be a habituation effect, so that the disturbance effects 
persist even with long-term therapy. Patients with intelligence impairment react 
to topiramate with the same cognitive disturbances as intellectually unaffected 
patients: Slow reactions, reduced language skills and reduced working memory 
can be found [12]. Even if these patients already have cognitive impairments, an 
additional drug-related deterioration should not be neglected, as this can have a 
fundamental impact on everyday competence and independence.
The following case study is intended to illustrate the possible scope of these 
cognitive effects caused by topiramate: A 20-year-old man introduced himself to 
the epilepsy centre. He developed epilepsy when he was 14 years old. At that time he 
attended the 8th grade of a secondary modern school (in German: Realschule). His 
former neuropediatric put him on topiramate, which he had tolerated subjectively 
well to this day (a current daily dose at admission 400 mg). He did not remember 
negative cognitive effects during school and did not complain about it when he 
was admitted. Soon after onset of epilepsy, the patient switched from secondary 
modern school to secondary school (in German: Hauptschule –a school with a lower 
level of graduation). In the end, he left school without graduating and subsequently 
found no apprenticeship training position, so at the time of admission to the 
epilepsy centre, he has been working in a supermarket as a temporary helper. While 
treatment optimization he was given an alternative anticonvulsant. Before changing 
his mediaction, he underwent neuropsycholgical examination (Figure 1).
With a dosage of 400 mg topiramate, the patient displayed significant per-
formance deficits in speech fluency, working memory and reaction speed were 
striking. These cognitive functions are associated with a successful performance 
in school: Linguistic skills are required to express yourself concretely and cor-
rectly in class and exams, to understand learning content and tasks and to apply 
or implement them. Working memory functions include the short-term holding 
and simultaneous manipulation of information – fundamental achievements to 
understand spoken language. If these skills are impaired or even slowed down, a 
student will not be able to adequately follow the lessons, which can lead to an overall 
failure in school. Though epilepsy can be accompanied with cognitive impairments 
or even global impairments of intelligence regardless of the medication, it is likely 
that a slight intellectual disability has caused the failed educational/professional 
career of our patient. After several months he came back to the epilepsy centre for 
further medication changes. At this point topiramate was completely discontinued. 
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The patient did not report any cognitive changes. However, he has started to catch 
up on the secondary school graduation. He even planned the next higher school 
graduation as well, to start apprenticeship as a car mechanic. We examined our 
patient again (Figure 2).
In contrast to the first neuropsychological examination, cognitive performances 
that have previously been below range (verbal fluency, reaction speed and working 
memory), were now within normal range. So, there were significant improvements 
in cognitive performance after stopping topiramate, which suggests that the deficits 
Figure 1. 
Note: Percentile rank 16 = lower average limit compared to a healthy control group; reaction time = tasks on 
reaction speed, comprehension = task to understand language, TPM = topiramate; with 400 mg TPM, the 
patient’s performance in almost all of the cognitive areas examined is below average compared to a healthy 
control group.
Figure 2. 
Note: Percentile rank 16 = lower average limit compared to a healthy control group; reaction time = tasks on 
reaction speed, comprehension = task to understand language, TPM = topiramate; after discontinuing TPM  
(0 mg), all examined cognitive areas showed normal findings and thus shows a clear improvement compared to 
the previous examination (400 mg TPM).
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found earlier (and thus probably also the failure in school) are related to the drug 
topiramate. Based on this case study, the possibly life-long social consequences due 
to the decision in favor of a certain drug at a certain point in patient patient’s life, is 
very impressive.
Zonisamide - similar to topiramate - can lead to cognitive disturbances with 
memory disorders, cognitive slowdown and word finding disorders [13]. In contrast 
to topiramate, a dose effect can be observed here (the higher the dose, the more 
serious the impairment). It is supposed that the negative interference effects fade, 
but this is not reported in all studies [14], so that under certain circumstances a 
therapy attempt could be considered despite the initial interference effects  
(e.g. if other anticonvulsants have not led to the desired therapeutic success despite 
increasing them to the limit of interference).
Benzodiazepines (clobazam, clonazepam, diazepam, lorazepam) are a group of 
anticonvulsant drugs with well-known and sometimes clear cognitive side effects 
(sedation, fatigue, concentration disorders). Apart from this, additional problems 
such as development of tolerance and the risk of addiction rule out these drugs for 
long-term therapy in epilepsy treatment. Apart from individual cases, they are used 
only as a bridge drug in medication changes and as an emergency medicine with 
one-time dose.
4. Cognitive side effects in children
Most studies examining unwanted interference effects mainly focus on adults. 
For the treatment of children there are often no separate data available. Transferring 
the study results just to children and adolescents is not advisable. Naturally, a 
child’s brain can, on the one hand, be restricted in its function by anticonvulsants, 
analogous to an adult brain. However, what is more is that unwanted interference 
effects can also adversely affect the further cognitive development. Disruptions in 
cognitive performances (e.g. working memory performance) can prevent or hinder 
the acquisition of new abilities and skills and may slow down the entire develop-
ment. Especially child epilepsy syndromes can be associated with severe intellectual 
disabilities and developmental delays. Additional negative interference effects of 
the medication are detrimental, so that the child may not be able to exploit its entire 
and eventually already reduced development potential.
Not all available anticonvulsants are approved for the treatment of epilepsy in 
children Compared to adults, children are more sensitive to the undesirable effects 
of drugs. Lamotrigine, levetiracetam, rufinamide, and gabapentin appear to have a 
rather minor effect on cognitive performance - Lamotrigine is said to even improve 
concentration disorders in children [8, 15]. Topiramate and zonisamide, however, 
can also have a negative effect on cognitive performance in children. Both substances 
lead to the cognitive interference effects in children that have been observed in 
adults as well: word-finding disorders, cognitive slowdown, memory and working 
memory disorders [12]. In contrast to adults deteriorations in information process-
ing speed, linguistic abilities, verbal learning and memory processes have also been 
described for valproic acid, oxcarbazepine and carbamazepine in children [16].
In contrast to adults, the drug-related cognitive deterioration is more serious 
in children, as further development and potential development in childhood and 
adolescence can be negatively influenced. Since school performance in particular 
plays an immense role in setting the course for later professional and social careers, 
the relevance of drug-related cognitive disruptive effects in childhood needs to be 
emphasized again, as the case study from the beginning illustrates very vividly.
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As mentioned earlier, there is a connection between valproic acid during 
pregnancy and the intellectual abilities of the unborn child [17]. Compared to 
children who were exposed to carbamazepine during pregnancy, children after 
exposure to valproic acid (especially in higher doses) achieve an IQ value up to 10 
points lower in the 6th year of life [18, 19]. Therefore this must be assessed as an 
irreversible, undesirable cognitive interference effect of valproic acid, even if this 
does not have a direct effect on the performance of the patient being treated, but 
rather on the unborn child who is been treated to. Since an association was also 
found between valproic acid during pregnancy and a later autism disorder in the 
child [20], therapy with valproic acid for women of childbearing age should be 
avoided.
5. Control of possible cognitive side effects
As the case study shows, the patient - and also the clinicians - are not always 
aware of the cognitive interference effects of anticonvulsants. In order to control 
possible influences on cognitive performance, it is therefore advisable - at least 
for certain substances (topiramate, zonisamide), to record the performance in a 
standardized manner before starting therapy, after reaching the target dose and if 
the patient reports any of new subjective cognitive complaints that occur during 
adjustment respectively. In specialized centres, this is carried out by experienced 
neuropsychologists as part of neuropsychological follow-up examinations with 
change-sensitive test procedures. In the outpatient neurological setting, however, 
a neuropsychological examination accompanying the drug setting is often not 
possible. Therefore, it is important to monitor potential changes by a detailed and 
repeated questioning of the patients or their caregivers about tolerability, including 
specific questions about possible changes/failures in school or work since the medi-
cation changeover, as well as test instruments specially designed for this question, 
such as EpiTrack and EpiTrack Junior (only available in German [21, 22]). Many 
different neuropsychological tests are available to control cognitive functions. The 
following cognitive performances should always be recorded: Attention (especially 
information processing speed), executive functions, language functions (especially 
verbal fluidity) and working memory. When selecting tests, care should be taken 
to ensure that the tests can be used repeatedly (e.g. parallel versions). In addition, 
possible mood changes should always be recorded.
In summary, because of their low negative impact on cognitive performance, 
certain anticonvulsants (e.g. lamotrigine, levetiracetam) are superior to others 
(topiramate, zonisamide, valproic acid). A monotherapy is always preferable to a 
combination therapy and a low dose to a high one, since most of the undesirable 
interfering effects described are both dose-dependent (lower dose - fewer or less 
interfering effects) and can tend to accumulate in combination therapies. In some 
cases, negative interfering effects can be counteracted by slowly increasing the 
medication (start low – go slow). However, this does not apply to all substances (see 
topiramate). In the case of drugs known to have undesirable cognitive interferences, 
the start of therapy should, if possible, be accompanied by neuropsychological 
follow-up examinations.
The best possible seizure control or seizure reduction is necessary for both the 
quality of life and the general performance of a patient. Therefore, substances with 
cognitive interference effects may sometimes be preferable to others (e.g. when 
other substances are not effective). In these cases, an individual assessment of the 
cost–benefit profile is necessary.
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6. Psychological side effects of anticonvulsant medication
Like people with other chronic diseases, patients with epilepsy suffer signifi-
cantly more often from psychological comorbidities such as depression or anxiety 
than healthy people. Treatment-refractory epilepsy and epilepsy with a seizure ori-
gin in temporal structures are affected with particular frequency [23]. Psychological 
complaints represent a significant impairment of the quality of life for those 
affected and require both precise diagnostics and consistent therapy. Treatment 
with mood-stabilizing, antidepressant drugs and accompanying psychological 
psychotherapy should therefore be considered for these patients. Concerns about 
possible proconvulsive effects of antidepressants are usually unfounded (with a 
single exception: amitriptyline) and should not prevent therapy.
However, before starting antidepressant therapy, it must be clarified whether 
the psychological complaints of the patient are possibly an undesirable interference 
of the anticonvulsant medication: Substances like topiramate, zonisamide, leveti-
racetam, and perampanel can have a negative impact on mood [13, 24]. Depressive 
and psychotic symptoms as well as increased aggressiveness were observed with 
topiramate. With levetiracetam, depressive symptoms can occur in individual cases 
as an undesirable drug interference effect as well. Much more common with this 
substance, however, are increased irritability and aggressiveness, which can unsettle 
both patients and relatives and in some cases lead to serious problems in the social 
environment. A dose reduction or a switch to another medication is advisable in 
both cases. For example, brivaracetam, which has been available since the beginning 
of 2016, promises to have a lower impact on psychological well-being with a similar 
mechanism of treatment [25–27].
With regard to psychological comorbidities, lamotrigine should be emphasized 
as an anticonvulsant with a probably additional antidepressant effect. Lamotrigine 
is therefore particularly recommended for patients with depression. However, 
lamotrigine can lead to unwanted sleep disorders, especially in the initial phase. This 
can be countered either by reducing the dose and then increasing it more slowly or 
by redistributing the individual doses during the day (higher dose in the morning, 
lower dose in the evening). In addition to lamotrigine, pregabalin also has a benefi-
cial effect on psychological comorbidities, especially anxiety and sleep disorders. 
Topiramate, which is used in lower doses also for migraine prophylaxis and addic-
tion therapy [28], can be used in patients with additional migraines - taking into 
account the above-mentioned factors relating to cognitive performance.
7. Psychological side effects in children
There is evidence that both topiramate and levetiracetam can lead to undesir-
able mood changes, particularly depression, irritability, personality changes, and 
hyperactivity in some children. Phenobarbital and primidone can lead to behavioral 
problems in children as well. Lamotrigine, on the other hand, has a mood-enhancing 
effect in children like in adults [29], and in children also has a positive effect on 
aggressiveness and impulsiveness [15]. Rufinamide appears to be unproblematic 
with regard to undesirable psychological disturbances [30].
In children and adolescents with intellectual disabilities, an increase in behavioral 
problems has occasionally been described with lamotrigine. Here, however, this 
might be due to the “lack of” sedation under lamotrigine compared to other anticon-
vulsants and the possible associated improved vigilance. If the medication switch to 
lamotrigine leads to behavioral problems, this might not be related to the medication 
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but to the possibly underlying disease and then of course it requires another han-
dling than that of a re-sedation.
In summary, it is advisable to check a possible relationship between a newly 
dosed anticonvulsant and the psychological complaints of a patient and then 
to counteract this by switching to an alternative medication. Since correlations 
between emotional side effects of anticonvulsants, a rapid dose escalation, an 
already existing mental illness and a family predisposition for mental illness were 
found, it is advisable to consider these aspects in drug selection [31].
8. Control of possible psychological side effects
To control possible psychological side effects, questionnaires can be used in 
addition to exploration and behavioral observation. The Beck Depression Inventory 
(BDI-II), Beck Anxiety Inventory (BAI) and the Hospital Anxiety and Depression 
Scale (HADS) are well-known and well established methods [32–34]. The 
Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) was devel-
oped specifically for people with epilepsy to detect depressive symptoms [35]. For 
children, the Child Behavior Checklist (CBCL-4-18) is recommended [36].
9. Alternatives to drug therapy
Due to the diverse side effects of anticonvulsants, alternative treatment methods 
(e.g. epilepsy surgery) should be considered early if therapy refractivity is determined. 
Therapy-refractory epilepsy is present if two suitable anticonvulsants dosed up to the 
interference limit in monotherapy and a combination therapy has not led to seizure 
freedom. For a clearly defined group of patients, epilepsy surgery is a safe, well-
established and very promising treatment option: For example, in the case of unifocal 
temporal lobe epilepsy due to proven hippocampal sclerosis, the chance of postopera-
tive freedom from seizures is up to 80%. In comparison, the chances of success of a 
further drug change for these patients are significantly lower.
10. Conclusion for practice
Since drug-based epilepsy therapy is mostly a long-term – sometimes a lifelong –  
therapy, it is of particular importance to take undesirable interfering effects into 
account. In addition to the frequency of seizures, cognitive and psychological side 
effects are particularly serious for the quality of life of patients. Therefore, when 
treating epilepsy with drugs, the focus should not only be on the desired effects on 
the frequency and severity of seizures, but also on possible undesirable effects on 
cognitive performance and mental health. Both the individual living conditions of 
the individual patient (e.g. possible later desire for children, upcoming training/
studies) as well as possible comorbidities (e.g. previous psychological comorbidity, 
intellectual impairment, cognitive partial performance disorders) must be taken into 
account when selecting drug therapy. Especially in children, patients with intel-
lectual disabilities and elderly patients (due to the increased vulnerability to undesir-
able disturbances), it is recommended to start with a low dose and slowly increase 
the dose (“start low, go slow”). For certain substances, the monitoring of cognitive 
functions and mood before and during the change/adjustment is necessary, e.g. 
based on neuropsychological follow-up examinations, special screening procedures 
and a detailed and specific questioning of the patient and the caregivers (Table 1).
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Abbreviations/anticonvulsants Possible cognitive side effects Possible emotional side 
effects
BR Bromine — o
BRV Brivaracetam o o
CBZ Carbamazepine (− In children) +
CLB Clobazam — Drug addiction problem
CLZ Clonazepam — Drug addiction problem
DZP Diazepam — Drug addiction problem
ESL Eslicarbazepine o o
GBP Gabapentine o (− In children)
LCM Lacosamide + o
LEV Levetiracetam o —
LTG Lamotrigine + +
LZP Lorazepam — Drug addiction problem
OXC Oxcarbazepine (+),(− In children) o
PER Perampanel (+) —
PB Phenobarbital — (− In children)
PHT Phenytoine — o
PGB Pregabalin — +
PRM Primidon — (− In children)
RFM Rufinamide o o
TPM Topiramate — —
VGB Vigabatrin Irreversible visual field defects
VPA Valproic acid (− In children, − in the unborn 
child)
+
ZNS Zonisamide — (−)
Legend: − negative interfering effect, + positive effect, o no known interfering effect.
Table 1. 
Overview of possible cognitive and psychological side effects of anticonvulsants.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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